EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia

Journal of Receptors and Signal Transduction

Volumn 32, Issue 3, 2012, Pages 142-149

  Kallel, Imen ^a   Khabir, Abdelmajid ^b   Boujelbene, Noureddine ^b   Abdennadher, Raoudha ^b   Daoud, Jamel ^b   Frikha, Mounir ^c   Aifa, Sami ^a   Sallemi Boudawara, Tahya ^b   Rebaï, Ahmed ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c HEDI CHAKER HOSPITAL   (Tunisia)

Author keywords

Breast carcinoma; EGFR; Prognosis; Triple negative profile

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE;

ADULT (18-64); AGED (<65); ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY (<50); SCARFF BLOOM RICHARDSON GRADE; TRIPLE NEGATIVE BREAST CANCER; TUNISIA;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUNISIA;

EID: 84860511478     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.664552     Document Type: Article

References (51)

1. Maalej M, Hentati D, Messai T, Kochbati L, El May A, Mrad K, Romdhane KB, Ben Abdallah M, Zouari B. Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study. Bull Cancer 2008, 95, E5-E9.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2, 127-137. (Pubitemid 33674041)
3. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003, 30, 3-11. (Pubitemid 36307612)
4. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 2007, 22, S3-S9. (Pubitemid 46730018)
5. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Hölscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001, 7, 1850-1855. (Pubitemid 32994816)
6. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical signifcance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13, 3-17.
7. Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 2002, 75 Suppl 1, S51-5; discussion S57. (Pubitemid 35015090)
8. Owens MA, Horten BC, Da Silva MM. HER2 amplifcation ratios by fuorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5, 63-69. (Pubitemid 38821193)
9. Gregory RK, Powles TJ, Salter J, Chang JC, Ashley S, Dowsett M. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000, 59, 171-175. (Pubitemid 30216140)
10. Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Hafty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys 2008, 72, 1056-1063.
11. BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11, 359-377.
12. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11, 155-168. (Pubitemid 28144151)
13. Khabir A, Ghorbel A, Daoud J, Frikha M, Drira MM, Laplanche A, Busson P, Jlidi R. Similar BCL-X but diferent BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect Prev 2003, 27, 250-255. (Pubitemid 36990242)
14. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996, 148, 1567-1576. (Pubitemid 26135897)
15. Corzo C, Tusquets I, Salido M, Corominas JM, Bellet M, Suarez M, Baró T, Fabregat X, Serrano S, Solé F. Characterization of HER1 (c-ERBB1) status in locally advanced breast cancer using fuorescence in situ hybridization and immunohistochemistry. Tumour Biol 2005, 26, 25-30. (Pubitemid 40529295)
16. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have diferent efects on survival. J Pathol 2002, 196, 17-25.
17. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002, 8, 3454-3460. (Pubitemid 35340721)
18. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200, 290-297. (Pubitemid 36827302)
19. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002, 20, 2319-2326. (Pubitemid 34441659)
20. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Tor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23, 1152-1160. (Pubitemid 46202271)
21. Park K, Han S, Shin E, Kim HJ, Kim JY. EGFR gene and protein expression in breast cancers. Eur J Surg Oncol 2007, 33, 956-960. (Pubitemid 47408738)
22. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007, 96, 801-807. (Pubitemid 46376621)
23. Shawarby MA, Al-Tamimi DM, Ahmed A. Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplifcation in Saudi breast cancer patients. Diagn Pathol 2011, 6, 57.
24. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplifcation in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005, 18, 1027-1033. (Pubitemid 41224492)
25. Press M F, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. HER-2 gene amplifcation, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efcacy in women with metastatic breast cancer. Clin Cancer Res 2008, 14, 7861-7870.
26. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53, 167-176. (Pubitemid 29161123)
27. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989, 34, 123-131. (Pubitemid 20061773)
28. Giuliania R, Durbecqa V, Di Leoa A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplifcation as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer, (2007), 43, 725-35. (Pubitemid 46509445)
29. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005, 16, 1755-1761. (Pubitemid 41631237)
30. Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantifed with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6, 4217-4225.
31. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9, R6.
32. Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001, 439, 62-69. (Pubitemid 32662519)
33. van Agthoven T, Timmermans M, Foekens JA, Dorssers LC, Henzen-Logmans SC. Diferential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994, 144, 1238-1246. (Pubitemid 24172086)
34. Schif R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004, 10, 331S-336S. (Pubitemid 38116639)
35. Osborne CK, Schif R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23, 1616-1622. (Pubitemid 46211414)
36. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001, 7, 4429s-4435s; discussion 4411s. (Pubitemid 34031592)
37. Schif R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003, 9, 447S-454S. (Pubitemid 36105786)
38. Arpino G, Wiechmann L, Osborne CK, Schif R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29, 217-233. (Pubitemid 351519691)
39. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712. (Pubitemid 19147683)
40. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet? Am J Clin Pathol 2004, 121 Suppl, S33-S49.
41. Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106, 758-765. (Pubitemid 36993401)
42. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16, 1647-1655. (Pubitemid 27151960)
43. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplifcation inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999, 274, 8865-8874. (Pubitemid 29164687)
44. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic efect on breast carcinoma survival. Cancer 2005, 103, 1770-1777. (Pubitemid 40563247)
45. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25-32. (Pubitemid 46120191)
46. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113, 357-370.
47. Akiyama F, Iwase H. Triple negative breast cancer: clinicopatho-logical characteristics and treatment strategies. Breast Cancer 2009, 16, 252-253.
48. Yao-Lung K, Dar-Ren C, Tsai-Wang C. Clinicopathological features of triple-negative breast cancer in Taiwanese women. Int J Clin Oncol 2011, 16, 500-505.
49. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008, 44, 2799-2805.
50. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast diferentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002, 82, 1525-1533. (Pubitemid 35332911)
51. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10, 5367-5374. (Pubitemid 39100473)